Literature DB >> 21883537

β2 -adrenergic receptor Thr164IIe polymorphism, blood pressure and ischaemic heart disease in 66 750 individuals.

M Thomsen1, M Dahl, A Tybjaerg-Hansen, B G Nordestgaard.   

Abstract

OBJECTIVES: The β(2) -adrenergic receptor (ADRB2) is located on smooth muscle cells and is an important regulator of smooth muscle tone. The Thr164Ile polymorphism (rs1800888) in the ADRB2 gene is rare but has profound functional consequences on receptor function and could cause lifelong elevated smooth muscle tone. We tested the hypothesis that Thr164Ile is associated with increased blood pressure, increased frequency of hypertension and increased risk of cardiovascular disease (CVD).
SUBJECTS: A total of 66 750 individuals from two large Danish general population studies were genotyped, and 1943 Thr164Ile heterozygotes and 16 homozygotes were identified.
RESULTS: Thr164Ile genotype was associated with increased systolic and diastolic blood pressure in women (trend: P = 0.04 and 0.02): systolic and diastolic blood pressure increased by 5% and 2%, respectively, in female homozygotes compared with female noncarriers. All female Thr164Ile homozygotes had hypertension compared with 58% of female heterozygotes and 54% of female noncarriers (chi-square: P = 0.001). Female Thr164Ile homozygotes and heterozygotes had odds ratios for ischaemic heart disease (IHD) of 2.93 (0.56-15.5) and 1.28 (1.03-1.61), respectively, compared with female noncarriers (trend: P = 0.007). These differences were not observed in men. Furthermore, Gly16Arg (rs1042713) and Gln27Glu (rs1042714) in the ADRB2 gene were not associated with blood pressure, hypertension or CVD either in the population overall or in women and men separately.
CONCLUSIONS: ADRB2 Thr164Ile is associated with increased blood pressure, increased frequency of hypertension and increased risk of IHD amongst women in the general population. These findings, particularly for homozygotes, are novel.
© 2011 The Association for the Publication of the Journal of Internal Medicine.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21883537     DOI: 10.1111/j.1365-2796.2011.02447.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  6 in total

1.  Network medicine analysis of COPD multimorbidities.

Authors:  Solène Grosdidier; Antoni Ferrer; Rosa Faner; Janet Piñero; Josep Roca; Borja Cosío; Alvar Agustí; Joaquim Gea; Ferran Sanz; Laura I Furlong
Journal:  Respir Res       Date:  2014-09-24

Review 2.  Genetics of Human Primary Hypertension: Focus on Hormonal Mechanisms.

Authors:  Worapaka Manosroi; Gordon H Williams
Journal:  Endocr Rev       Date:  2019-06-01       Impact factor: 19.871

3.  Alpha1a-adrenoceptor genetic variant induces cardiomyoblast-to-fibroblast-like cell transition via distinct signaling pathways.

Authors:  Maren Kleine-Brueggeney; Irina Gradinaru; Ekaterina Babaeva; Debra A Schwinn; Anush Oganesian
Journal:  Cell Signal       Date:  2014-05-15       Impact factor: 4.315

4.  Shared genetic variants between serum levels of high-density lipoprotein cholesterol and wheezing in a cohort of children from Cyprus.

Authors:  Panayiotis K Yiallouros; Panayiotis Kouis; Ourania Kolokotroni; Sonia Youhanna; Savvas C Savva; Kleanthi Dima; Aikaterini Zerva; Danielle Platt; Nicos Middleton; Pierre Zalloua
Journal:  Ital J Pediatr       Date:  2016-07-13       Impact factor: 2.638

Review 5.  Mechanisms Linking COPD to Type 1 and 2 Diabetes Mellitus: Is There a Relationship between Diabetes and COPD?

Authors:  Sangmi S Park; Jessica L Perez Perez; Brais Perez Gandara; Christina W Agudelo; Romy Rodriguez Ortega; Huma Ahmed; Itsaso Garcia-Arcos; Cormac McCarthy; Patrick Geraghty
Journal:  Medicina (Kaunas)       Date:  2022-08-01       Impact factor: 2.948

6.  Correlation in gene expression between the aggravation of chronic obstructive pulmonary disease and the occurrence of complications.

Authors:  Yuchen Cai; Runhan Liu; Xinhe Lu; Qiming Zhang; Xinwei Wang; Huijing Lian; Haohua Wang
Journal:  Bioengineered       Date:  2020-12       Impact factor: 3.269

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.